The objectives of this study were to  compare and investigate the incidences and risks of venous thromboembolism (VTE) between the two groups of patients with community-acquired pneumonia (CAP) and COVID-19 pneumonia.

All statistical tests were two-sided, and P<0.05 was considered statistically significant. All data management and analyses were performed by IBM SPSS, version 24, software (SPSS, Inc, Chicago, IL). Of the 616 patients, 256 had COVID-19 pneumonia, and 360 patients had CAP. VTE’s overall rate was 2% in the COVID-19 pneumonia group and 3.6% in the CAP group, respectively. In these two groups, 15.6% of the COVID-19 pneumonia patients and 10% of the CAP patients were categorized as high risk for VTE (Padua score, >4), which were significantly different. In those high-risk patients, VTE incidence was 12.5% in the COVID-19 pneumonia group and 16.7% in the CAP group. Subgroup analysis of the critically ill patients showed that the VTE rate was 6.7% in the COVID-19 group versus 13% in the CAP group. In-hospital mortality of COVID-19 and CAP was 6.3% and 3.9%, respectively.

In conclusion, this study suggested that COVID-19 pneumonia was associated with a hypercoagulable state. However, VTE’s rate in COVID-19 pneumonia patients was not significantly higher than that in CAP patients.